Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.60 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.60 |
| ▸ | HTR3B | O95264 | 4/20 | 0.60 |
| ▸ | HTR3A | P46098 | 4/20 | 0.60 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.60 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2229923 | 1.00 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4201780 | 0.92 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4201779 | 0.92 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4198180 | 0.88 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4198182 | 0.88 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3500036 | 0.88 | CHRNA7 (0.69) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3497048 | 0.88 | CHRNA7 (0.69) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3497046 | 0.88 | CHRNA7 (0.69) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9597197 | 0.87 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2230266 | 0.86 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344636-B1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HUGHES HOWARD MED INST (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2344636-B1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HUGHES HOWARD MED INST (US) | 2017-12-06 | — | — | EP | disclosed |
| US-8435762-B2 | Chimeric ligand-gated ion channels and methods of use thereof | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435762-B2 | Chimeric ligand-gated ion channels and methods of use thereof | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435762-B2 | Chimeric ligand-gated ion channels and methods of use thereof | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2344636-A2 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | Howard Hughes Medical Institute (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100130420-A1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130420-A1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130420-A1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010042799-A2 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042799-A2 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130420-A1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3E 633/4885HTR3B 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.